{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:53:10Z","timestamp":1774288390558,"version":"3.50.1"},"reference-count":26,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Haematol"],"abstract":"<jats:p>Introduction: The standard induction chemotherapy in newly diagnosed acute myeloid leukemia (AML) is 7 days cytarabine and 3 days daunorubicin. However, older and frail patients cannot be treated intensively. Before hypomethylating agents (HMA) plus venetoclax (VEN) was established we formulated a more tolerable induction therapy for these patients using continuous infusions of reduced doses of cytarabine (A) and idarubicin (IDA) in combination with ATRA (A), the (A)-AIDA regimen and trying to reach noteworthy and relevant remission rates with acceptable toxicities in this special population. Methods: Between 1998 and 2015 older\/frail patients with newly diagnosed or relapsed AML received (A)-AIDA. Treatment consisted of cytarabine 100 mg\/m2\/d d1\u20135 and IDA 5 mg\/m2\/d d1\u20135 as continuous infusion. Since 2003 ATRA (45 mg\/m2\/d d4\u20136, 15 mg\/m2\/d d7\u201328) was added in some patients. Results: 154 patients received (A)-AIDA, median age was 71 years. In 40% the AML was secondary, 15.6% had relapsed AML. The complete remission rate was 41%, 7% reached a partial remission, the median overall survival was 7 months. No significant differences of remission rates regarding various known risk factors for outcome with (A)-AIDA were detected. Conlusion: Recent studies established HMA\/VEN as first-line treatment for older\/frail AML patients. Because (A)-AIDA is equally effective in patients with secondary or relapsed AML or ECOG &gt;1, this regimen is an interesting treatment option for patients uneligible to HMA\/VEN regimens.<\/jats:p>","DOI":"10.1159\/000545792","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T12:01:50Z","timestamp":1746532910000},"page":"155-167","source":"Crossref","is-referenced-by-count":0,"title":["Dose Reduced Induction Therapy (A)-AIDA in Patients with Acute Myeloid Leukemia, Being Unfit for Standard 7+3 Chemotherapy and Literature Review of Acute Myeloid Leukemia Treatment in Unfit\/Older AML Patients"],"prefix":"10.1159","volume":"149","author":[{"given":"Karin","family":"Mayer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonie","family":"Birk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katjana","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo G.H.","family":"Schmidt-Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"von Lilienfeld-Toal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Brossart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Glasmacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinna","family":"Hahn-Ast","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.066100"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1406184"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403528"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0901409"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v79.2.313.bloodjournal792313"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(87)90113-5"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb03396.x"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13378"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11516"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki221"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22496"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.9429"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621664"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30210-6"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117344"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/cells9102310"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3724"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276485"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.0890"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.09.019"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.027516"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-250878"}],"container-title":["Acta Haematologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000545792","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000545792","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:01:21Z","timestamp":1774285281000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000545792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3,23]]},"published-print":{"date-parts":[[2026,3,26]]}},"URL":"https:\/\/doi.org\/10.1159\/000545792","archive":["Portico"],"relation":{},"ISSN":["0001-5792","1421-9662"],"issn-type":[{"value":"0001-5792","type":"print"},{"value":"1421-9662","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]}}}